Healthcare
Medexus Pharmaceuticals Inc.(MEDXF)
Live Price
Offline$2.85
-1.38% today
1Y Change
+20.61%
Window
Jun 25, 2025 → Jun 17, 2026
- Market Cap
- $100.00M
- Revenue Growth
- -4.2%
- EPS Growth
- +985.3%
- Dividend Yield
- 0.0%
Coverage: 246 bars · Jun 25, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Medexus Pharmaceuticals Inc. (MEDXF) is a Healthcare stock with a market cap of $100.00M and listed on OTC. The stock last traded around $2.85 and up 20.6% across the available one-year price window (Jun 25, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of -4.2%, EPS growth of +985.3%, a dividend yield of 0.0%. What stands out right now is revenue -4.2%, EPS +985.3%, free cash flow +15.5% with operating margin 2.8% and ROIC 2.8%. Valuation is more restrained than many high-expectation growth names at price/sales 1.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines MEDXF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-4.2% vs +7.6% peer median
Operating Margin
Below sector median
+2.8% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating picture looks softer than before
Revenue is at -4.2% and EPS is at +985.3%, with operating margin around 2.8%.
Benchmark Edge
MEDXF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
MEDXF
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
MEDXF Max Drawdown
-24.20%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for MEDXF and SPY.
Company Overview
Medexus Pharmaceuticals Inc.
Other OTC
Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. It focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, and allergy. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, a prescription allergy medication. Its products portfolio also includes Treosulfan, a bifunctional alkylating agent for allogeneic hematopoietic stem cell transplantation; Trispan, a triamcinolone hexacetonide injectable suspension; and Gleolan, an optical imaging agent indicates for patients with glioma symptoms. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Bolton, Canada.
- Leadership
- Kenneth d'Entremont
- IPO Date
- Nov 27, 2017
- Employees
- 82
- Street Address
- 35 Nixon Road
- Mailing
- Bolton, ON, L7E 1K1
- Region
- Bolton, ON, CA
- Reporting Currency
- USD
- Investor Line
- 877 633 3987
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- —
- EV/EBITDA
- 6.7
- Price/Sales
- 1.0
- Price/Book
- 1.8
Growth
- Revenue
- -4.2%
- EPS
- +985.3%
- Free Cash Flow
- +15.5%
Profitability
- Gross Margin
- 53.9%
- Operating Margin
- 2.8%
- Net Margin
- -0.3%
- ROE
- -0.5%
- ROIC
- 2.8%
Balance Sheet
- Debt/Equity
- 0.49
- Current Ratio
- 1.12
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.